Shuttle Executes LOI with Molecule.ai
1. Shuttle Pharma signed a non-binding letter of intent to acquire Molecule.ai. 2. Molecule.ai offers AI-driven tools for drug discovery and development. 3. Acquisition could reduce costs and enhance accuracy in therapeutic candidate evaluation. 4. Shuttle plans to pay $10 million for Molecule.ai based on milestones. 5. Molecule.ai's technology aims to accelerate the drug development timeline.